辛伐他汀、普伐他汀治疗原发性高胆固醇血症的疗效比较

The efficacy and safety of simvastatin and pravastatin in treatment of primary hypercholesteremia

目的:观察辛伐他汀(Sim)、普伐他汀(Pra)治疗原发性高胆固醇血症的疗效及安全性.方法:采用随机分组、平行对照的方法.81例患有原发性高胆固醇血症病人.随机分成2组,Sim组39例.Pra组42例.结果:经过12wk治疗,Sim组TC、TG、LDL-C分别由(7.42±1.33).(2.23±1.16),(4.60±1.18)mmol/L下降到(5.69±1.17),(1.65±0.75),(3.07±0.94)mmol/L(P<0.01).HDL-C治疗前后分别为(1.30±0.28).(1.28±0.49)mmol/L下降了1.5%(P>0.05);Pra组TC、TG、LDL-C分别由(7.14±1.20),(2.32±1.30),(4.64±1.37)mmol/L下降到(5.76±1.13),(1.88±1.07),(3.28±1.30)mmol/L(P<0.01),HDL-C治疗前后分别为(1.27±0.24),(1.31±0.29)mmol/L(P>0.05);2组血脂改变程度、疗效及不良反应经统计学处理无差异(P>0.05).结论:Sim 5mg/d,Pra 10mg/d对原发性高胆固醇血症的病人可获得较好的疗效.且使用方便.

AIM:To evaluate the efficacy and safety of simvastatin(Sim)and pravastatin (Pra)in patients suffered from primary hypercholesteremia. METHODS: A randomized, pa-ralleled-controlled study was performed, 81 patients including 38 males, 42 females, aged 40~80 years (mean, 61. 3±10. 2) were randomized to two treatment groups: Sim group and Pra group. The dose of Sim group was 5mg qn, po and that of Pra group was 10mg qn,po. RESULTS: After 12 weeks treatment,concentration(mmol/L)of TC,TG,LDL-C decreased from (7. 42± 1. 33), (2. 23± 1.16), (4. 60± 1.18)to(5.69±1.17), (1. 65±0. 75), (3. 07± 0. 94)mmol/L(P<0. 01),respectively in Sim group and those decreased from (7.14±1. 20), (2. 32±1. 30), (4. 64± 1. 37)mmol/Lto(5. 76±1.13), (1. 88± 1. 07), (3. 28±1. 30)mmol/L (P<0. 01) respectively in Pra group. The percentages of TC,TG,LDL-C decrease were 23%,26%,33%respectively in Sim group and those were 19% ,19% ,29%respectively in Pra group. The concentration (mmol/L) of HDL-C before treatment and after treatment were (1. 30±0. 28)and (1.28±0. 49)mmol/L(P>0.05)respectively in Sim group and those were (1. 27±0. 24)and (1. 31±0. 29)mmol/L(P>0. 05)respectively. No serious side-effects were found in two treatment groups. There were no significant differences between Sim and Pra groups in efficacy and safety(P>0. 05). CONCLUSION -Simvastatin and pravastatin are ef-- 165 -fective and no serious side-effects in treatment of primary hypercholesteremia.